<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02108639</url>
  </required_header>
  <id_info>
    <org_study_id>AI443-110</org_study_id>
    <nct_id>NCT02108639</nct_id>
  </id_info>
  <brief_title>To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet</brief_title>
  <official_title>An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Fixed Dose Combination Formulation of DCV, ASV, and BMS-791325 in Subjects With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End-stage Renal Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the effect of renal function on the blood levels of DCV, ASV, BMS-791325.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IND Number: 79,599/101,943

      Primary Purpose: Other - Phase 1 Clinical Pharmacology study to determine the effect of renal
      impairment on the exposure of DCV, ASV, BMS-791325 (fixed dosed combination) and BMS-791325
      given in multiple doses

      Fixed dose combination (FDC)

      Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325 (DCV 3DAA FDC)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) for DCV, ASV, BMS-791325 and BMS-794712</measure>
    <time_frame>For Groups A-D: Day 1 to Day 10 and for Group E: Day 1 to Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve in 1 dosing interval (AUC(TAU)) for DCV, ASV, BMS-791325 and BMS-794712</measure>
    <time_frame>For Groups A-D: Day 1 to Day 10 and for Group E: Day 1 to Day 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration at 12 hours (C12) for (DCV, ASV, BMS-791325) and BMS-948158</measure>
    <time_frame>For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed concentration (Tmax) for (DCV, ASV, BMS-791325) and BMS-948158</measure>
    <time_frame>For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CLT/F) for (DCV, ASV and BMS-791325 only)</measure>
    <time_frame>For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (Ctrough) for (DCV, ASV, BMS-791325), BMS-794712 and BMS-948158</measure>
    <time_frame>For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax fraction unbound (Cmaxfu) for (DCV, ASV, BMS-791325), BMS-794712 and BMS-948158</measure>
    <time_frame>For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13</time_frame>
    <description>BMS-948158 may also be analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(TAU) fraction unbound (AUC(TAU) fu) for (DCV, ASV, BMS-791325), BMS-794712 and BMS-948158</measure>
    <time_frame>For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13</time_frame>
    <description>BMS-948158 may also be analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein Binding for DCV, ASV, BMS-791325 and BMS-794712</measure>
    <time_frame>1 and 4 hours postdose on Day 10 (all subjects) and Day 12 (Group E only)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total amount recovered in urine (URt) for (DCV, ASV, BMS-791325) and BMS-794712</measure>
    <time_frame>For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total percent of administered dose recovered in urine (%URt) for (DCV, ASV, and BMS-791325 only)</measure>
    <time_frame>For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLR) for DCV, ASV, BMS-791325, and BMS-794712</measure>
    <time_frame>For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) for BMS-948158</measure>
    <time_frame>For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in 1 dosing interval (AUC (TAU)) for BMS-948158</measure>
    <time_frame>For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety based on occurrence of Adverse Event (AEs), Serious adverse event (SAEs) and AEs leading to discontinuation</measure>
    <time_frame>For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety based on abnormalities in vital sign measurements</measure>
    <time_frame>For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety based on findings on ECG measurements and physical examinations</measure>
    <time_frame>For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety based on Marked abnormalities in clinical laboratory test findings</measure>
    <time_frame>For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>DCV 3DAA FDC + BMS-791325</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A to D: DCV 3DAA FDC + BMS-791325 oral tablets on specific days
Group E: DCV 3DAA FDC + BMS-791325 oral tablets on specific days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCV 3DAA FDC</intervention_name>
    <arm_group_label>DCV 3DAA FDC + BMS-791325</arm_group_label>
    <other_name>Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-791325</intervention_name>
    <arm_group_label>DCV 3DAA FDC + BMS-791325</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Subjects in Group A must be in good health and have normal renal function

          -  Subjects in Groups B-E may have clinical, Electrocardiogram (ECG) and laboratory
             findings consistent with their degree of renal dysfunction

          -  Women of childbearing potential (WOCBP) and male participants must agree to follow the
             required contraceptive methods

        Exclusion Criteria:

          -  Subjects in Group A must not have any significant acute or chronic illnesses

          -  Subjects in Groups B-E must not have uncontrolled or unstable cardiovascular,
             respiratory, hepatic, gastrointestinal, endocrine, hematopoietic, and/or neurological
             disease within 6 months of screening

          -  Subjects in Groups B-E may not have evidence of rapidly deteriorating renal function,
             defined as a screening creatinine clearance (CLcr) which has decreased from a previous
             CLcr by 50% within the last 3 months

          -  Prior exposure to DCV, ASV or BMS-791325 within 3 months prior to study drug
             administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology Of Miami Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center For Clinical Research - Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2014</study_first_submitted>
  <study_first_submitted_qc>April 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2014</study_first_posted>
  <last_update_submitted>July 9, 2014</last_update_submitted>
  <last_update_submitted_qc>July 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

